Trial Profile
A Phase II Study of Letrozole and RAD001 (Everolimus) in Patients With Advanced or Recurrent Endometrial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Letrozole (Primary)
- Indications Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- 27 Sep 2023 Planned End Date changed from 30 Apr 2023 to 30 Apr 2028.
- 27 Sep 2023 Planned primary completion date changed from 30 Apr 2022 to 30 Apr 2028.
- 16 Nov 2022 Planned End Date changed from 30 Apr 2022 to 30 Apr 2023.